Gilead Sciences reports Q3 earnings Oct 30. Discover estimates, analyst revisions, and past performance stats.

The timing of the renewed support is pivotal. South Africa is preparing to roll out Lenacapavir, a groundbreaking long-acting ...

When President Donald Trump issued an executive order suspending all foreign aid to South Africa, in January this year, we immediately set about finding solutions. Among the most pressing was to ...

South Africa has made history by becoming the first African nation to register Lenacapavir, a revolutionary long-acting ...

Self-Cav, South Africa’s AI chatbot on WhatsApp, empowers teens with 24/7 support on HIV prevention, PrEP, mental health, and ...

South Africa approved lenacapavir on October 21, 2025—a twice-yearly injection offering near-100% HIV protection. This ...

By William Baloyi When President Donald Trump issued an executive order suspending all foreign aid to South Africa, in ...

SAHPRA chief executive Dr Boitumelo Semete-Makokotlela said the product is “the most effective HIV prevention measure thus ...

Biotech bigwig Gilead Sciences, Inc. GILD is scheduled to report third-quarter 2025 result s on Oct. 30, after market close.

EFF statement on South Africa registering the twice-a-year anti-HIV injection, Lenacapavir ...

Camber Pharmaceuticals’ parent company, Hetero, a global company specializing in active pharmaceutical ingredients and ...

Through a US$ 29 million grant, South Africa will receive enough medicine to provide HIV prevention to 450 000 people at high ...